Ascendis Pharma A/S to Present at Upcoming Investor Conferences
COPENHAGEN, Denmark, May 8, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at several upcoming investor conferences.
Logo - http://photos.prnewswire.com/prnh/20150128/171828LOGO
| Event: |
Bank of America Merrill Lynch 2015 Health Care Conference - Las Vegas, NV |
| Date: |
Wednesday, May 13, 2015 |
| Time: |
10:00 a.m. PDT / 1:00pm EDT |
| Event: |
UBS Global Healthcare Conference - New York, NY |
| Date: |
Wednesday, May 20, 2015 |
| Time: |
8:30 a.m. EDT |
| Event: |
Bio€quity Europe - Vienna, Austria |
| Date: |
Wednesday, May 20, 2015 |
| Time: |
11:00 a.m. CET / 5:00 a.m. EDT |
Links to audio webcasts of the Bank of America Merrill Lynch 2015 Health Care Conference and the UBS Global Healthcare Conference will be posted to the Ascendis Pharma website at www.ascendispharma.com, and will be available until June 30, 2015.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of bestinclass therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.
The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed a Phase 2 study in adults with growth hormone deficiency, or GHD. Ascendis Pharma is currently conducting a Phase 2 study of TransCon Growth Hormone in children with GHD. Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension, or PAH. In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners. These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.
Contact:
Investor contact:
Martin Auster, M.D.
Chief Business Officer
+1 (650) 617-3403
ma@ascendispharma.com
Media contact:
Marion Janic
Rooney & Associates
+1 (212) 223-4017
mjanic@rooneyco.com
Share this article